More Qantas executive changes this morning…and potentially more at its eagerly anticipated AGM?
Nick Sundich, October 16, 2023
More Qantas executive changes were announced this morning. And there could be more to come as the company seeks to rebuild its reputation.
SIGN UP FOR THE STOCKS DOWN UNDER NEWSLETTER NOW!
Qantas executive changes
Qantas Loyalty CEO Olivia Wirth, will depart the business in February 2024. Her departure is noteworthy because she was seen as one of two candidates to succeed Alan Joyce and also because of how significant the Loyalty business has been to Australia’s flag carrier. Also departing was the CEO of QantasLink John Gissing, who has been with the company nearly 25 years.
It also announced the hiring of a handful of new executives – the most notable was the appointment of Catherine Walsh as Chief People Officer. And being promoted to new CEO of Qantas Domestic was Chief Customer Officer Markus Svensson.
More movements to come at the board level?
The company is holding its AGM next week and to say it will be interesting will be an understatement. Michael LÉstrange will be retiring at the AGM and Maxine Brenner and Jacqueline Hey will depart in February 2024. And Richard Goyder has promised to step away in November next year.
Former American Airlines executive Doug Parker and Heather Smith have been put forward but need approval at the AGM. Belinda Hutchinson and Todd Sampson are up for re-election. Normally the election of board directors is a box-checking exercise at AGMs. But with the issues the company has been facing – the ACCC and legal penalties, reputational baggage and industry headwinds – it may not be so this time around.
What are the Best stocks to invest in right now?
Check our buy/sell stock tips
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Analysts aren’t optimistic about iron ore prices in 2025, will they be right and what will it mean for iron ore stocks?
In which direction will iron ore prices in 2025 go? Chinese trade data would suggest upwards, and indeed prices jumped…
Paradigm Biopharmaceuticals’ flagship drug Zilosul will be in Phase 3 in 2025
Paradigm Biopharmaceuticals (ASX:PAR) has been listed for nearly a decade with the goal of bringing its flagship drug pentosan polysulfate…
Findi (ASX:FND): Its quadrupled in 12 months off the back of financial services in India
Until Findi (ASX:FND) came along, there were practically no ASX companies making money from India (or at least not many…